biopharmaceutical that is engineering the next generation of peptide...][More Releases From This Source]## Explore[Health Care & Hospitals][Computer & Electronics][Biotechnology][Artificial Intelligence][News Releases in Similar Topics]---- -- Decoy Therapeutics Joins Webull Corporate Connect Service Platform [Accessibility Statement] Skip Navigation- Connect with the Company on Webull [here]CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Co ...

Company Overview - Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing peptide conjugate therapeutics targeting serious unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [3] - The company utilizes machine learning and artificial intelligence tools alongside high-speed synthesis techniques to design and manufacture its drug candidates [3] - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund, Google AI startup program, and NVIDIA Inception program [3] Upcoming Presentation - Decoy Therapeutics will participate in the Corporate Connect Webinar Series hosted by Webull Financial on February 10-11, 2026 [1] - Rick Pierce, the CEO of Decoy Therapeutics, will provide a corporate overview and discuss a new class of antiviral therapeutics capable of targeting multiple viral pathogens with a single drug [2] Financial and Strategic Partnerships - The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) through the QuickFire Challenge award, in collaboration with Johnson & Johnson Innovation – JLABS [3]

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the Company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation. The "What This Means" segment provides ...

Core Insights - Decoy Therapeutics, a subsidiary of Salarius Pharmaceuticals, is developing influenza fusion inhibitors using its proprietary IMP3ACT™ platform, which shows promising in silico binding energy to viral target proteins, indicating potential anti-flu activity [1][2] - The collaboration with Texas Biomedical Research Institute aims to conduct in vitro testing of these inhibitors across various influenza strains, including H5N1 avian flu, addressing the urgent need for effective antiviral treatments [1][3] Company Developments - Salarius has completed a merger with Decoy Therapeutics and raised $8 million through a public offering, focusing on advancing its pipeline of peptide conjugate therapeutics [4] - The company aims to leverage its IMP3ACT platform to create a single antiviral therapeutic effective against influenza, COVID-19, and RSV, potentially addressing a significant global commercial opportunity [4][11] Industry Context - Seasonal influenza and related illnesses result in over 10 million medical visits annually in the U.S., highlighting a substantial unmet medical need [4] - The World Health Organization reports approximately 1 billion cases of seasonal influenza each year, with severe cases leading to 290,000 to 650,000 respiratory deaths, emphasizing the critical need for new antiviral therapies [7][11] Technological Advancements - The IMP3ACT platform utilizes machine learning and rapid synthesis techniques to design and manufacture peptide conjugate therapeutics, enhancing the speed and efficiency of drug development [3][8] - Decoy's technology has shown effectiveness against multiple human coronaviruses and RSV, indicating its potential for broad application in infectious diseases [9][11]

As filed with the Securities and Exchange Commission on October 21, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 7 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 2450 Holcombe Blvd. Suite X Houston, TX 77021 713 ...

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement, as of October 10, 2025, following prior compliance with Listing Rule 5550(a)(2) on September 9, 2025 [1][2] - The company is in the process of a planned merger with Decoy Therapeutics, which is expected to create multiple value-creating opportunities through Decoy's peptide conjugate therapeutics pipeline [3][5] - The combined company will be led by Decoy's co-founders and Salarius' acting CEO, indicating a strong leadership structure for the new entity [6] Compliance and Monitoring - Salarius is now fully compliant with all Nasdaq listing requirements, which is crucial for the merger with Decoy Therapeutics [2] - The company will be under a Mandatory Panel Monitor for one year starting October 10, 2025, to ensure ongoing compliance with the Equity Standard Requirement [4] Merger Details - The merger agreement with Decoy Therapeutics involves a business combination where Decoy will merge with a wholly owned subsidiary of Salarius, forming a new entity named Decoy Therapeutics [3] - Decoy's pipeline focuses on unmet medical needs in respiratory infectious diseases and GI oncology, with plans to advance a pan-coronavirus antiviral and other programs within the next 12 months [7] Product Development - The combined company aims to enhance Decoy's IMP3ACT platform for rapid design and manufacturing of peptide conjugate therapeutics, while also incorporating Salarius' SP-3164 into a targeted drug candidate [5] - Salarius' lead candidate, seclidemstat, is being studied for hematologic cancers, with ongoing clinical trials at MD Anderson Cancer Center [8][11]

As filed with the Securities and Exchange Commission on September 23, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 2450 Holcombe Blvd. Suite X Houston, TX 77021 7 ...

As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Copies to: Andrew L. Strong, Esq. Stephen M. Nicolai, Esq. Hogan Lovells US LLP 609 Main Street, Suite 4200 Houston, TX 77002 (713) 632-1400 Jeffrey Kuras, Esq. Honigman L ...

As filed with the Securities and Exchange Commission on July 31, 2025 Registration No. 333-284368 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SALARIUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 2450 Holcombe Blvd. Suite X Houston, TX 77021 713-91 ...

Core Insights - Decoy Therapeutics, Inc. is set to merge with Salarius Pharmaceuticals, Inc., with the new entity retaining the name Decoy Therapeutics, following the completion of the merger [1][10] - Renowned MIT Professor Robert S. Langer will join Decoy's Scientific Advisory Board, bringing extensive expertise in drug delivery systems and tissue engineering [1][2][3] Company Overview - Decoy Therapeutics is a preclinical-stage biotechnology company focused on developing peptide-conjugate therapeutics targeting unmet medical needs, particularly in respiratory viruses and gastrointestinal cancers [8] - The company utilizes a proprietary IMP3ACT platform that integrates machine learning and AI for rapid design and synthesis of novel antiviral and cancer therapies [5][7] Scientific Advisory Board - Dr. Robert S. Langer's appointment to the Scientific Advisory Board is expected to enhance Decoy's capabilities in drug design and development, particularly in dosage forms and administration routes [3][4] - Dr. Langer's contributions to the field include pioneering work that has led to transformative medicines, such as Roche's Avastin and Moderna's Spikevax [2][4] Technology and Innovation - Decoy's IMP3ACT platform allows for the rapid computational design of peptide-conjugate drugs, which have shown effectiveness against various human coronaviruses and other viral pathogens [5][7] - The technology leverages peptide chemistry to create multimeric conjugates that improve drug-like properties and pharmacokinetics [7] Financial and Strategic Position - Decoy has secured financing from institutional investors and non-dilutive capital sources, including the Massachusetts Life Sciences Seed Fund and the Google AI startup program [8] - The merger with Salarius is structured such that Decoy investors will own approximately 86% of the merged company, while Salarius stockholders will own about 14% [10]